Veracyte (VCYT) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- $0.54
- Estimate
- $0.43
- Surprise
- +25.1%
- Score at report (before → after)
- 6.2 → 6.2/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
How the report landed
Veracyte (VCYT) beat the $0.43 estimate with diluted EPS of $0.54 — a large 25.1% upside surprise. TrendMatrix's engine moved from Buy (Wait) (6.2/10) to Hold at 6.2/10 after the report.
Where TrendMatrix's rating stands now
TrendMatrix currently rates VCYT Hold at 6.3/10.
4 of the last 4 quarters beat the estimate; this quarter's +25.1% surprise compares with a +42.6% four-quarter average. Next scheduled report: 2026-11-03.
What supports the rating
- Sector modifier (Healthcare): +0.5
- Strong earnings beat streak (4/4)
What argues against it
- Concentration risk — Product: Decipher Prostate and Afirma tests
- Concentration risk — Supplier: sole suppliers for reagents and equipment
- Negative momentum
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $40.87
- Price target
- $50.82
- Stop
- $38.89
- Upside to target
- +24.3%
- Reward-to-risk
- 2.7:1
The stock trades at 29.2× trailing but 20.9× forward earnings — consensus estimates already build in a substantial earnings recovery.
Model outputs from TrendMatrix’s engine as of 2026-09-14 — shown for context, not personalized investment advice.
VCYT at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Diagnostics & Research
- Market cap
- $3.29B
- P/E (fwd)
- 20.9
- P/E (ttm)
- 29.2
- 52-week range
- $29.45–$60.91
- Off 52-week high
- 32.9%
- RSI (14)
- 45
- Volume vs avg
- 0.79×
- Score today
- 6.3/10